{"id":"W2047759229","doi":"10.1159/000336892","title":"First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study","year":2012,"lang":"en","type":"article","venue":"Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline; Pfizer","keywords":"Bevacizumab; Medicine; Triple-negative breast cancer; Internal medicine; Regimen; Metastatic breast cancer; Oncology; Population; Taxane; Breast cancer; Chemotherapy; Progression-free survival; Surgery; Cancer; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003846951,0.0001572237,0.0007111696,0.0002837904,0.00006822715,0.000002601736,0.0001016841,0.00009296516,0.0004290283],"category_scores_gemma":[0.00003225005,0.00009783654,0.0001727952,0.0007343176,0.00006436281,0.00005112213,0.00001653657,0.0001186361,0.000001846924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003975159,"about_ca_system_score_gemma":0.00009454423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003266854,"about_ca_topic_score_gemma":0.008024998,"domain_scores_codex":[0.998795,0.000223393,0.0003513631,0.0001951021,0.0001242517,0.000310883],"domain_scores_gemma":[0.9987352,0.0006771087,0.0002100274,0.0001732508,0.0001412821,0.00006309657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008010281,0.01024399,0.9353479,0.000008888726,0.002734802,0.000005089068,0.01559349,0.00002813101,0.00004687465,0.00001691801,0.000299803,0.02766387],"study_design_scores_gemma":[0.024748,0.01147783,0.9561872,0.000008397016,0.003164932,0.000003314474,0.001393966,0.0002359668,0.0001147061,0.00001430072,0.002565682,0.00008573454],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954565,0.0004306634,0.000006181859,0.001149129,0.0001921073,0.002101483,0.000170626,0.00001195603,0.0004813849],"genre_scores_gemma":[0.9977847,0.0002677614,0.00002822228,0.0005428001,0.000168161,0.0009556496,0.0001044951,0.00001350238,0.0001346856],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02757813,"threshold_uncertainty_score":0.4938528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05396276108214242,"score_gpt":0.407239581350104,"score_spread":0.3532768202679615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}